Status:
UNKNOWN
Added Value in Combined Use of Fusion Imaging and Contrast-enhanced Ultrasonography
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Korean Liver Cancer Association
Conditions:
Contrast Media, Liver, Biopsy, Fusion
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
So far, there have been studies showing that the CEUS-grafted technique has added value in biopsy and RFA, but no studies have compared the group using only fusion and the group using CEUS+fusion. The...
Detailed Description
Despite the rapid development of tumor markers and liver imaging, pathological confirmation is still necessary for atypical liver lesions that do not meet imaging criteria. US guided procedures are wi...
Eligibility Criteria
Inclusion
- Patients scheduled for ultrasound biopsy to confirm local liver lesions
- Adults over 18
- Patients who underwent multi-phasic liver CT or MRI within 6 weeks prior to the procedure
- Patients who understand and agree to the explanation and consent form and submit the consent form
Exclusion
- Non-adaptive patients with ultrasound contrast agents (eg acute respiratory failure, heart disease, egg allergy, pregnant women, lactating women)
- Those who have difficulty obtaining proper liver ultrasound images A. Patient cooperation is not possible B. If it is difficult to obtain an image that is appropriate for the researcher's judgment (atrophy of the right lobe of the liver, a bowel is located between the liver and the abdominal wall, etc.)
Key Trial Info
Start Date :
June 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04487288
Start Date
June 2 2020
End Date
December 30 2022
Last Update
April 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea